Star Health PAT Rises 16% to ₹911 Cr in FY26; Combined Ratio Improves

BANKINGFINANCE
Whalesbook Corporate News Logo
AuthorKavya Nair|Published at:
Star Health PAT Rises 16% to ₹911 Cr in FY26; Combined Ratio Improves

Star Health reported a 16% rise in consolidated Profit After Tax to ₹911 Crore for FY26. The insurer also saw its Combined Ratio improve to 98.8% from 101.1% in the previous year, indicating better underwriting efficiency.

Star Health Posts 16% Rise in FY26 Consolidated Profit to ₹911 Crore

Consolidated Profit After Tax (PAT) for FY 2026: ₹911 Crore Consolidated Gross Written Premium (GWP) for FY 2026: ₹20,384 Crore Reader Takeaway: Improved underwriting efficiency and strong digital strategy underpin growth, with focus on portfolio quality over aggressive expansion. ## What just happened Star Health and Allied Insurance Company Ltd. announced its financial results for the fiscal year ended March 31, 2026. The company reported a consolidated Profit After Tax (PAT) of ₹911 Crore, a notable increase of 16% compared to ₹787 Crore in FY 2025. Gross Written Premium (GWP) also saw significant growth, reaching ₹20,384 Crore in FY 2026, up from ₹17,553 Crore in FY 2025. A key operational highlight is the improvement in the Combined Ratio, which stood at 98.8% on an IND AS basis for FY 2026, a marked improvement from 101.1% in the previous fiscal year. This metric indicates enhanced underwriting efficiency, where the company is earning more from premiums than it is paying out in claims and expenses. On a standalone basis (IGAAP), the company reported a GWP of ₹18,621.92 Crore and a PAT of ₹556.98 Crore. ## Why this matters The improved profitability and combined ratio signal Star Health's successful strategy of prioritizing portfolio quality and strengthening controls over aggressive top-line growth. For investors, this suggests a more sustainable and efficient business model. The company's strong retail market share of 31% and an extensive proprietary agent force of over 8.3 Lakh also underscore its market leadership and distribution strength. ## The backstory FY 2026 was described as a year of 'deliberate recalibration' for Star Health. Management focused on enhancing fraud controls and claims servicing, alongside strengthening the quality of its business portfolio. This strategic shift aimed to build a more robust foundation for long-term growth. ## What changes now The company is poised to continue its growth trajectory by strengthening its retail health franchise through disciplined underwriting and prudent capital allocation. The focus remains on maintaining a strong solvency ratio, which stood at 2.05 times (IGAAP), providing a substantial capital buffer. ## Risks to watch Star Health is actively monitoring and investing in AI-enabled mechanisms to combat Fraud, Waste, and Abuse (FWA). Geopolitical and macroeconomic uncertainties are also identified as watch points, though the company views health insurance as a crucial financial safeguard in such times. ## Peer comparison While specific peer data for the current fiscal year is not detailed in the filing, Star Health's reported Combined Ratio of 98.8% suggests improved operational efficiency compared to its own previous performance. The retail market share of 31% highlights its dominant position in the health insurance sector. ## Context metrics * **Consolidated GWP Growth:** Increased from ₹17,553 Crore (FY 2025) to ₹20,384 Crore (FY 2026). * **Consolidated PAT Growth:** Rose from ₹787 Crore (FY 2025) to ₹911 Crore (FY 2026). * **Combined Ratio Improvement:** Decreased from 101.1% (FY 2025) to 98.8% (FY 2026). * **Digital Collections:** 96% of fresh retail business premiums collected digitally. ## What to track next Investors will be keen to observe the company's ability to sustain high renewal ratios, the successful integration of its Salesforce-based CRM transformation, and the performance of new optional covers introduced under the 'Star Flexi' rider framework. Monitoring the continued improvement in underwriting metrics will also be crucial.
Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.